Established in 1990, ALPCO started off as an importer and distributor of immunoassay-based products serving the North American life science markets. Currently, the company offers its proprietary and distributed diagnostics solutions to more than 60 collaborating partners across the world.
ALPCO has been engaged in offering specialty immunoassay products (IVD and RUO), which are focused mainly on the clinical gastroenterology and diabetes research segments.
The New Hampshire based in vitro diagnostics company will use the investment to support its global growth initiatives. These include the expansion of its diagnostics test kit offering, enlarging its geographic footprint, and powering internal R&D product development and production operations.
Eric Lev – General Partner at Ampersand Capital Partners said: “With our operating and investment experience within the laboratory products and diagnostics markets, coupled with an injection of growth capital, we believe that ALPCO is poised to be a market leader in specialty immunoassay products worldwide.”
ALPCO’s founders Richard Conley and Jan Conley will remain as its shareholders, while Sean Conley will continue to head the business as CEO.
Sean Conley said: “We have always been committed to offering our customers the solutions they need to both advance the quality of care and enable better medical research. I am confident that this partnership with Ampersand will allow us to grow as an organization and better serve our customers as we invest in our infrastructure and service offering.”